What is Proacta?
Proacta operates as a full-service Contract Research Organization (CRO) with a specialized focus on conducting oncology clinical trials, particularly First-in-Human studies for novel cancer therapies. Leveraging decades of expertise, the company offers bespoke solutions to the biopharmaceutical industry, ensuring the execution of high-quality and meticulously managed clinical trials. Their comprehensive service portfolio spans from pre-clinical development through to full clinical trial management, providing the flexibility to accommodate the distinct requirements of each project. Proacta is dedicated to advancing excellence and fostering innovation through close collaboration with sponsors, aiming to achieve optimal outcomes in oncology research.
How much funding has Proacta raised?
Proacta has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Proacta
PPP
Public-Private Partnership
What's next for Proacta?
The substantial late-stage funding indicates Proacta is poised for significant scaling and expansion of its operational capabilities. This capital injection is likely to fuel advancements in their service offerings, potentially broadening their reach in First-in-Human studies and other critical oncology trial phases. Strategic partnerships and further technological integration can be anticipated as Proacta solidifies its market leadership and continues to support the development of next-generation cancer treatments.
See full Proacta company page
